The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Patient selection in the treatment of CLL
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, explains the rationale behind patient selection and treatment of chronic lymphocytic leukemia (CLL) in the era of chimeric antigen receptor (CAR) T-cell therapy, commenting on the benefits of using CAR-T in earlier lines and in combination with ibrutinib. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Transcript
For CLL, of course, at this point we don’t have a lot of data, but we have some very compelling studies and evidence that CLL is a perfect target for copies and treatment. From the current evidence we have, it seems that the most active way to apply CARs in CLL, is not to use it in very late lines, and to combine it with ibrutinib, and that seems to lower toxicity and also increase the response rates in terms of MRD...
For CLL, of course, at this point we don’t have a lot of data, but we have some very compelling studies and evidence that CLL is a perfect target for copies and treatment. From the current evidence we have, it seems that the most active way to apply CARs in CLL, is not to use it in very late lines, and to combine it with ibrutinib, and that seems to lower toxicity and also increase the response rates in terms of MRD. So, I think it will probably be used the latest when a patient did not respond to at least two different treatments with an inhibitor. So, if a patient is even resistant, for instance, through a BTK.
Read more...
